Earth Science Pharma’s inaugural project is the rollout of the MSN-2 medical device.
This device is brought by our Chief Scientific Officer Dr. Michel Aubé, who conceived the idea while conducting his post-doctorate studies.
3Q/2016: MSN-2 is clinically proven to successfully sample for chlamydia
4Q/2016: The MSN-2 medical device was announced
1Q/2017: Testing begins to certify MSN-2 for gonorrhea sampling.
Q2/2017: Inauguration of the MSN-2 manufacturing facility
Q4/2017: Product branding and ecommerce website completed
Initial MSN-2 product release to overseas markets only
Q4/2017: Clinical study to detect gonorrhea in the same sample completed
Q1/2018 Product and service will test for both diseases using one sample
Q2/2018 Manufacturing facility earns ISO-13485 accreditation
Q3/2018 MSN-2 received FDA and Health Canada approvals for Class II medical device, product and service launched in North American markets.
As of Q2/2017, Earth Science Pharma is in the early planning stages of four projects which are either entirely in-house or are being developed with partners. None of these projects reached the timeline stage.
These projects are:
1- Expanding the capability of the MSN-2 product and service to allow it to detect other STI, such as trichomonase and HPV, from the same sample.
2- Expanding the capability of the MSN-2 product and service to allow it to detect up to 10 different non-sexually transmitted vaginal infections using an existing PCR Multiplex test.
3- Development of a proprietary home PCR test to detect chlamydia at a lower cost than the commercial service.
4- Development of a prophylactic vaccine to prevent chlamydia